You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

ruxolitinib

( RUX-oh-LI-ti-nib )
Funding:
Exceptional Access Program
  • ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
  • ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Other Name(s): Jakavi®
Appearance: tablet in various strengths and shapes

Patient Info Sheet

May 2018

What it is used for

  • For treatment of enlarged spleen and / or condition affecting the bone marrow called myelofibrosis
  • To control blood counts (such as red blood cells) that may be too high due to a bone marrow condition called polycythemia vera (PV)


You might also be interested in